par Fernández-Cuesta, Lynnette;Oakman, Catherine;Falagan-Lotsch, Priscila;Smoth, Ke-Seay;Quinaux, E;Buyse, Marc;Dolci, Stella;de Azambuja, Evandro ;Hainaut, Pierre;Dell'orto, Patrizia;Larsimont, Denis ;Francis, P;Crown, John;Piccart-Gebhart, Martine ;Viale, Giuseppe;Leo, Angelo;Olivier, Magali
Référence Breast cancer research, 14, 3, page (R70)
Publication Publié, 2012
Référence Breast cancer research, 14, 3, page (R70)
Publication Publié, 2012
Article révisé par les pairs
Résumé : | Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to retrospectively explore the prognosis and predictive values of TP53 somatic mutations in the BIG 02-98 randomized phase III trial in which women with node-positive breast cancer were treated with adjuvant doxorubicin-based chemotherapy with or without docetaxel. |